Quest Diagnostics二季度业绩超预期并再次上调2026年收入和调整后EPS指引

Earnings Call Insights: Quest Diagnostics (DGX) Q2 2026
Management View
- "Our strong performance in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights... In the quarter, we grew revenues by over 10%... and increased volume from our collaborations with Corewell Health and Fresenius Medical Care." (Chairman, CEO & President James Davis)
- "Our implementation of automation and AI across our business is driving continuous improvements in quality and productivity... With our strategic execution and demographic and technological trends driving sustained demand, we are again raising our guidance for the year." (Chairman, CEO & President Davis)
- "In oncology, we achieved key milestones for Haystack MRD during the quarter. New York State approved the test... This approval allows us to extend our commercial efforts to all 50 states." (Chairman, CEO & President Davis)
- "We also became the largest reference lab to extend access to cancer tests such as Haystack MRD through Flatiron Health's OncoEMR Molecular Profiling Integration platform." (Chairman, CEO & President Davis)
- "In the second quarter, consolidated revenues were $3.04 billion, up 10.2% versus the prior year... Total volume measured by the number of requisitions increased 13.1%... Excluding these 2 relationships, volumes grew by 4.1%." (Executive VP & CFO Sam Samad)
Outlook
- "We now expect revenues to be between $11.95 billion and $12.05 billion... Reported EPS to be in a range of $9.97 to $10.17 and adjusted EPS in a range of $11.05 to $11.25." (Executive VP & CFO Samad)
- "Our 2026 full year guidance reflects... Nova expenses are unchanged for the full year, but we anticipate increased spend in the second half of the year compared to prior expectations. Higher fuel costs in the second half of 2026 versus prior expectations." (Executive VP & CFO Samad)
- "Operating margin is expected to expand versus the prior year." (Executive VP & CFO Samad)
- "We now expect revenues to be between $11.95 billion and $12.05 billion" vs. "We now expect revenues to be between $11.78 billion and $11.9 billion" in the prior quarter’s guidance update. (Executive VP & CFO Samad)
- "Adjusted EPS in a range of $11.05 to $11.25" vs. "Adjusted EPS in a range of $10.63 to $10.83" in the prior quarter’s guidance update. (Executive VP & CFO Samad)
Financial Results
- $3.04B revenue vs. $2.97272044B analyst estimate for Q2 2026; $3.12 adjusted EPS vs. $2.82 analyst estimate for Q2 2026. (Executive VP & CFO Samad; analystsEstimates)
- "Reported operating income in the second quarter was $459 million... On an adjusted basis, operating income was $502 million... Operating income as a percent of revenues was impacted by investments in Project Nova and the lower operating margin rate associated with the ramp of the Corewell Co-Lab business." (Executive VP & CFO Samad)
- "The improvement in EPS in the second quarter was largely driven by strong organic operating performance as well as the favorable resolution of various tax contingencies, which contributed $0.10 of EPS in the quarter." (Executive VP & CFO Samad)
- "Cash from operations was $875 million year-to-date through the second quarter... Cash from operations to be approximately $1.8 billion and capital expenditures to be approximately $550 million." (Executive VP & CFO Samad)
Q&A
- "I'm just curious what you're seeing across that [hospital] channel right now... are you seeing a building hospital deal pipeline?" (Erin Wright, Morgan Stanley) "So we're not seeing any slowdown in our hospital business, whether it's Co-Lab or reference... You mentioned bad debt. That is not a concern with hospitals or any of our clients." (Chairman, CEO & President Davis)
- "Previously, you had 30 basis points of a headwind because of changes in ACA and Medicaid... if you still have something in the updated guidance around potential headwinds?" (Lisa Gill, JPMorgan) "We still think it's a 30 basis point impact... But that's not translating into our business." (Chairman, CEO & President Davis) "We're still assuming for the full year that there's a 30 basis point impact on revenue from the ACA exchange subsidy expiration." (Executive VP & CFO Samad)
- "Can you give us the offsets that help build towards that second half margin ramp..." (Michael Cherny, Leerink) "We're expecting Nova expenses in the second half to be about 70% of the full year... continued growth in volumes... [and] less of a dilutive impact from Corewell and Fresenius in the second half." (Executive VP & CFO Samad)
- "Anything... changes in the full year revenue guide?" (Lu on for Michael Ryskin, Bank of America) "It's a $250 million impact -- positive impact on our revenues this year... We anticipate to scale this up to a JV next year... and... launch that JV in early next year." (Executive VP & CFO Samad)
- "Can you make us comfortable... talk about like what your bad debt is as a percentage of revenue" (Ann Hynes, Mizuho) "Patient concessions... hovers around... 5% or so of revenues... [and] has also not seen any material... deterioration." (Executive VP & CFO Samad) "We have pretty tight controls over patient balances." (Chairman, CEO & President Davis)
- "I wanted to ask about PAMA... potential reimbursement outcomes?" (Noah on for Tycho Peterson, Jefferies) "There's 3 possible outcomes on PAMA..." (Chairman, CEO & President Davis)
Sentiment Analysis
- "How are you thinking about potential reimbursement outcomes?" and repeated probing on hospitals, DSOs, bad debt, and margin cadence reflected a slightly negative analyst tone focused on reimbursement and cash-collection risk. (Multiple analysts)
- "We are again raising our guidance for the year" and "we are not seeing any slowdown" reflected a slightly positive management tone in prepared remarks, while Q&A responses stayed confident and specific on policy and collections. (Chairman, CEO & President Davis)
- "We still think it's a 30 basis point impact" and "not translating into our business" in Q2, versus Q1’s "we haven't seen really that negative impact in Q1" framing, kept management’s stance consistent while providing more granular utilization/mix detail in Q2. (Chairman, CEO & President Davis; Executive VP & CFO Samad)
Quarter-over-quarter comparison
- "We are again raising our guidance for the year" (Q2) followed Q1’s "we are raising our revenue and EPS guidance for the year," with Q2 increasing the full-year ranges further while adding new second-half cost callouts: "increased spend in the second half" for Nova and "higher fuel costs." (Executive VP & CFO Samad)
- Analysts shifted from Q1 emphasis on consumer partnerships, AI, and CRUSH to Q2 emphasis on hospital bad debt, DSOs, ACA exchange impacts, and PAMA outcomes, while continuing to revisit Corewell/Fresenius mix and margins. (Multiple analysts)
Risks and Concerns
- "There could be new rates... effective January 1" and "if we don't get results done this year, we will push, obviously, for another delay" summarized policy uncertainty around PAMA and the RESULTS Act. (Chairman, CEO & President Davis)
- "Total revenue per requisition was down 2.8%... due to the Corewell and Fresenius business mix" and "higher fuel costs" and "increased spend" on Nova described key near-term headwinds management cited alongside expected operating margin expansion. (Executive VP & CFO Samad)
Final Takeaway
Management described Q2 as being driven by broad-based clinical demand and collaboration-led volume, highlighted New York State approval and broader ordering integration for Haystack MRD, and raised full-year guidance again to $11.95B-$12.05B revenue and $11.05-$11.25 adjusted EPS, while reiterating a 30-basis-point ACA exchange headwind assumption and outlining second-half cost pressure from higher Nova spend timing and fuel.
Read the full Earnings Call Transcript